| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005362048 |
| P356 | DOI | 10.1007/S11064-013-1117-X |
| P698 | PubMed publication ID | 23918203 |
| P50 | author | Senthilkumar S Karuppagounder | Q50276692 |
| P2093 | author name string | Vishnu Suppiramaniam | |
| Subramaniam Uthayathas | |||
| Muralikrishnan Dhanasekaran | |||
| Manuj Ahuja | |||
| Bessy Thrash-Williams | |||
| P2860 | cites work | Amantadine for dyskinesia in Parkinson's disease | Q24248660 |
| Methamphetamine toxicity and messengers of death | Q24647617 | ||
| The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity | Q28261448 | ||
| Methamphetamine-induced neurotoxicity: the road to Parkinson's disease | Q28270691 | ||
| Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport | Q28301517 | ||
| Motor impairments after methamphetamine-induced neurotoxicity in the rat | Q28317276 | ||
| Mouse strain-dependent effect of amantadine on motility and brain biogenic amines | Q28340488 | ||
| Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? | Q28343251 | ||
| A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine | Q29547303 | ||
| Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. | Q31112202 | ||
| SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity | Q31923969 | ||
| Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers | Q32068833 | ||
| Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression | Q33314722 | ||
| Cytotoxic and genotoxic potential of dopamine | Q33603762 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease | Q33607256 | ||
| The role of excitotoxicity in neurodegenerative disease: implications for therapy | Q33639170 | ||
| Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice | Q33899756 | ||
| Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity | Q34260540 | ||
| Therapeutic brain concentration of the NMDA receptor antagonist amantadine | Q34368565 | ||
| Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. | Q34407523 | ||
| Non-cholinergic strategies for treating and preventing Alzheimer's disease | Q34991505 | ||
| Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. | Q35087517 | ||
| Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. | Q35128313 | ||
| Treatment of methamphetamine abuse: research findings and clinical directions | Q35155969 | ||
| A guide to neurotoxic animal models of Parkinson's disease | Q35603488 | ||
| Mitochondrial complex I plays an essential role in human respirasome assembly | Q35868845 | ||
| Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? | Q36089442 | ||
| Methamphetamine causes microglial activation in the brains of human abusers. | Q36801473 | ||
| Expression of c-fos mRNA in the basal ganglia associated with contingent tolerance to amphetamine-induced hypophagia | Q37362143 | ||
| Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity | Q39298185 | ||
| Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists | Q41154685 | ||
| Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. | Q41509275 | ||
| Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism | Q42216349 | ||
| Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. | Q42541545 | ||
| Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease | Q42542290 | ||
| Role of peroxynitrite in methamphetamine-induced dopaminergic neurotoxicity and sensitization in mice | Q43006506 | ||
| Neurotoxic effects of methamphetamine. | Q43288344 | ||
| Dopamine and norepinephrine uptake by rat brain synaptosomes: relative inhibitory potencies of 1- and d-amphetamine and amantadine | Q43548674 | ||
| Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum | Q44456150 | ||
| Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence | Q44750276 | ||
| Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice | Q45111655 | ||
| High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. | Q45188930 | ||
| Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates | Q46207450 | ||
| Free radical production induced by methamphetamine in rat striatal synaptosomes | Q46395250 | ||
| Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization | Q46549728 | ||
| Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite | Q46639973 | ||
| Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity | Q46862060 | ||
| Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. | Q48144142 | ||
| Antiparkinsonian drugs and in vitro excitotoxicity | Q48405676 | ||
| Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. | Q48434037 | ||
| Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum | Q48440490 | ||
| Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats. | Q48464731 | ||
| Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders | Q48469640 | ||
| Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine | Q48478951 | ||
| Role of dopamine in the neurotoxic effects of methamphetamine. | Q48486498 | ||
| Amantadine and catecholamine uptake | Q48741417 | ||
| The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates | Q48882113 | ||
| Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment | Q48944131 | ||
| Evaluation of neuroprotective and anti-fatigue effects of sildenafil | Q50276650 | ||
| Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. | Q51030734 | ||
| New lessons from old drugs: amantadine and Parkinson's disease | Q64891648 | ||
| Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism | Q67687976 | ||
| Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents | Q70810207 | ||
| Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist | Q71859363 | ||
| Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid | Q72098398 | ||
| Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain | Q72426971 | ||
| P433 | issue | 10 | |
| P921 | main subject | neurotoxicity | Q3338704 |
| P304 | page(s) | 2084-2094 | |
| P577 | publication date | 2013-08-06 | |
| P1433 | published in | Neurochemical Research | Q15716728 |
| P1476 | title | Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity | |
| P478 | volume | 38 |
| Q23921525 | Antiviral drugs |
| Q39356354 | Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review. |
| Q55284097 | The Main Molecular Mechanisms Underlying Methamphetamine- Induced Neurotoxicity and Implications for Pharmacological Treatment. |
| Q38819196 | The Role of Oxidative Stress in Methamphetamine-induced Toxicity and Sources of Variation in the Design of Animal Studies |
Search more.